Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy NuCana stock
Learn how to easily invest in NuCana stock.
NuCana plc is a biotechnology business based in the US. NuCana shares (NCNA) are listed on the NASDAQ and all prices are listed in US Dollars. NuCana employs 27 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in NuCana
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – NCNA – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
NuCana stock price (NASDAQ: NCNA)Use our graph to track the performance of NCNA stocks over time.
NuCana shares at a glance
|Latest market close||$2.77|
|52-week range||$1.88 - $7.07|
|50-day moving average||$2.56|
|200-day moving average||$2.77|
|Wall St. target price||$1,168.72|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.03|
Buy NuCana shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy NuCana stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
NuCana price performance over time
|1 week (2022-01-13)||2.21%|
|1 month (2021-12-21)||15.90%|
|3 months (2021-10-21)||7.78%|
|6 months (2021-07-22)||13.99%|
|1 year (2021-01-22)||-55.03%|
|2 years (2020-01-22)||-46.20%|
|3 years (2019-01-22)||14.63|
|5 years (2017-01-18)||N/A|
|Gross profit TTM||$0|
|Return on assets TTM||-25.36%|
|Return on equity TTM||-41.71%|
|Market capitalisation||$149.2 million|
TTM: trailing 12 months
NuCana share dividends
We're not expecting NuCana to pay a dividend over the next 12 months.
NuCana share price volatility
Over the last 12 months, NuCana's shares have ranged in value from as little as $1.88 up to $7.07. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NuCana's is 0.6555. This would suggest that NuCana's shares are less volatile than average (for this exchange).
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase III clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with metastatic pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors; and NUC-7738, a nucleoside analog that is in Phase I clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. NuCana plc has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017.
NuCana in the news
Netflix quietly admits streaming competition is eating into growth
Microsoft's $68.7 billion deal for Activision once again shows big tech's dominance over legacy media
Supreme Court vaccine mandate ruling won't bar companies from demanding Covid shots for workers — Biden vows to advocate for that
Frequently asked questionsWhat percentage of NuCana is owned by insiders or institutions?
Currently 0.049% of NuCana shares are held by insiders and 36.256% by institutions. How many people work for NuCana?
Latest data suggests 27 work at NuCana. When does the fiscal year end for NuCana?
NuCana's fiscal year ends in December. Where is NuCana based?
NuCana's address is: 3 Lochside Way, Edinburgh, United Kingdom, EH12 9DT What is NuCana's ISIN number?
NuCana's international securities identification number is: US67022C1062 What is NuCana's CUSIP number?
NuCana's Committee on Uniform Securities Identification Procedures number is: 67022C106
More guides on Finder
Today’s top U.S. stocks: Las Vegas Sands (LVS ↑15.3%), Wynn Resorts Limited (WYNN ↑9.1%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Thursday’s top U.S. stocks: Taiwan Semiconductor Manufacturing Company Ltd. (TSM ↑8.4%), Lam Research Corporation (LRCX ↑6.1%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut savings review
Donut earns up to 10% APY, but you must have an iOS device.
Monie savings review
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Tesla roars into 2022 after December drop
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
How to buy Austin Gold (AUST) stock when it goes public
Everything we know about the Austin Gold IPO, plus information on how to buy in.
How to buy VinFast stock when it goes public
Everything we know about the VinFast IPO, plus information on how to buy in.
NFT-funded LinksDAO moves $10.5 million closer to buying a golf course
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.
Ask an Expert